key: cord-0880222-uvw1hwjf
authors: Shimizu, Kazuki; Checchi, Francesco; Warsame, Abdihamid
title: Disparities in Health Financing Allocation among Infectious Diseases in Ebola Virus Disease (EVD)-Affected Countries, 2005–2017
date: 2022-01-18
journal: Healthcare (Basel)
DOI: 10.3390/healthcare10020179
sha: 80b5e549cc463d4946e56039aa53e215c2d10df6
doc_id: 880222
cord_uid: uvw1hwjf

The Ebola virus disease (EVD) outbreaks impacted the population health due to overstretched health systems and disrupted essential health services. Despite a call to achieve equal financial allocation depending on public health needs, there has been scant examination of the fairness of investment among infectious diseases. This study analyzes the extent to which equitable development assistance for health (DAH) has been provided in accordance with disease burden in EVD-affected countries. Estimates of disability-adjusted life years (DALYs) in the Global Burden of Disease (GBD) Study 2017 and DAH Database 1990–2019 in 2005–2017 were analyzed by disease category: vaccine-preventable diseases (VPDs), HIV/AIDS, malaria, tuberculosis, and EVD. HIV/AIDS generally recorded higher ratios of DAH per DALYs (DAH/DALYs). Malaria and tuberculosis showed different trends by country, and VPDs generally presented lower ratios. In West Africa in 2013–2016, DAH/DALYs surged in EVD and fluctuated in HIV/AIDS and malaria. Tuberculosis and VPDs consistently recorded lower ratios. To achieve the risk reduction during and after health emergencies, optimal funding allocation between diseases based on the disease burden is warranted in the pre-emergency period, along with measurement of immediate health needs of populations in real-time during an emergency.

Since its discovery in 1976, the Ebola virus disease (EVD) has been a serious public health threat. Historically, all EVD outbreaks originated in Africa, and according to the Center for Disease Control (CDC) classification, African countries have experienced 19 EVD outbreaks between 2000 and 2020, of which eight occurred in the Democratic Republic of the Congo (DRC) [1] . The global attention toward EVD has surged over the past 10 years. In particular, the 2013-2016 EVD outbreak in West Africa became the largest EVD outbreak in history, recording 28,652 cases and 11,325 deaths (case fatality risk: 39.5%) [2] . The 2018-2020 EVD outbreak in the DRC and Uganda subsequently became the second largest one in the history, with 3480 cases and 2287 deaths (case fatality risk: 65.7%) [3] . The outbreak was recognized as one of the "most complex health emergencies" in the world [4] ,

To satisfy the objectives of this study, VPDs, HIV/AIDS, malaria, tuberculosis, and EVDs have been compared. VPDs are comprised of twelve diseases: pneumococcal meningitis; H influenzae type B (Hib) meningitis; diphtheria; whooping cough; tetanus; measles; acute hepatitis B; rotavirus; pneumococcal pneumonia; H influenzae type B (Hib) pneumonia; poliomyelitis; and rubella. This selection is based on the definition of Financing Global Health 2018 datasets, and the search strategy used for calculating DAH for child and newborn vaccines were referenced from the User Guide [45, 46] . DAH is composed of financial and in-kind resources that originate in international development agencies and are disbursed to low-and middle-income countries (LMICs) for maintaining and improving population health [47] . To analyze the evolution of DAH in EVD-affected countries, the data were extracted from the Development Assistance for Health Database 1990-2019 [45] . DAH specific to each disease was denoted as below by following the definition of the Institute for Health Metrics and Evaluation (IHME) DAH Database (2019) User Guide [45] , and the amount of DAH extracted between 2005 and 2017 was categorized by disease. The supplementary methods annex of Financing Global Health 2018 demonstrated that dollars were deflated by the US GDP deflator, which is specific to the reporting year, and keyword searches were conducted for concluding "a subset of global health channels that provide project-level data with project titles or descriptions [46] ". Data sources of DAH are summarized in Table 1 . To measure the burden of diseases, injuries, and risk factors on population health, the concept of disability-adjusted life years (DALYs) has been introduced [48, 49] , and it is widely used by international organizations, including WHO, for quantifying disease burden [50] . DALYs are useful in that both traditional epidemiological data on mortality and information about the loss of quality of life with several value choices are combined, and the disease burden is quantified by taking time as a unit [48, 49] . Currently, results of the Global Burden of Disease (GBD) Study have been widely used at national, regional, and global levels for strategically considering the resource allocation in various public health programs [51] . To analyze the evolution of DALYs in EVD-affected countries, both the all-cause DALYs and the DALYs specific to HIV/AIDS, malaria, tuberculosis, and EVD between 2005 and 2017 were extracted from the Global Burden of Disease Collaborative Network and arranged by following the GBD 2017 Online Tools Overview [52] . The age group was set as all ages (age group ID: 22) , and the cause ID is presented in Table 2 . Regarding VPDs, DALYs specific to diseases that are classified into child and newborn vaccines in DAH were extracted (Table 3) . To follow the definition of a child by IHME [47] , DALYs were extracted by specifying the age group under five years (age group ID: 1) and calculated by the following formula:

The absolute DAH and DALYs over time were calculated by year and shown by disease in EVD-affected countries. Data in Guinea, Liberia, and Sierra Leone were also compiled as West Africa region. To conduct these analyses, only the point estimated data were used. To match DAH with DALYs, the ratio of DAH to DALYs (unit: USD/DALYs) is represented as:

where i is the country and j is the type of disease. Namely, ratios were calculated by total DAH and all-cause DALYs, as well as those specific to VPDs, HIV/AIDS, malaria, and tuberculosis, and EVD, and aggregated by region and country. The point estimates and 95% uncertainty intervals of DALYs data were used for the analysis.

DAH for countries in West Africa and DRC is shown in Figure 1A ,B, respectively.

Healthcare 2022, 10, x FOR PEER REVIEW 5 of 15

DAH for countries in West Africa and DRC is shown in Figure 1A ,B, respectively. In 2005, the total DAH for West Africa was USD 121 million, and the two dominant categories, HIV/AIDS (22.8%) and malaria (16.5%), were followed by VPDs (5.6%). While minor decreases were observed in 2011 and 2013, there was an upward tendency of total DAH on the whole, which exceeded USD 300 million in 2012, and HIV/AIDS and malaria continuously comprised the larger proportion. It quickly soared to USD 1.22 billion in 2014 and finally peaked at USD 1.58 billion in 2015 before plummeting to USD 525 million in 2017, due to a surge of DAH for EVD from USD 662 million in 2014 to USD 1.12 billion in 2015, which constituted 70.7% of total DAH for that year.

The breakdown of DAH for each country in West Africa and exact values are presented in Supplementary Figure S1 and Supplementary Table S1, respectively. In 2005, the total DAH for Liberia was only USD 25.0 million, which was below compared to DAH received by Guinea (USD 44.8 million) and less than half of Sierra Leone (USD 51.1 million). However, it has jumped up to USD 82.4 million in 2008, which was higher compared to the other two countries, and the trend continued by 2013. Among the disease category, HIV/AIDS was more funded compared in the pre-emergency period in Sierra Leone except in 2006, while in Liberia, the amount of DAH for malaria generally exceeded DAH for HIV/AIDS, except for some changes in 2007 and 2013. DRC received higher investment through DAH compared to countries in West Africa. The total DAH for the DRC continued to grow to USD 821 million in 2017. In 2005-2008, investment for HIV/AIDS accounted for more than 20% of total DAH. DAH for malaria dramatically increased to USD 199 million in 2012, which constituted 28.7% of total DAH, and continuously exceeded that DAH for HIV/AIDS in 2012-2017. DAH for VPDs increased to USD 108 million in 2014. However, a marked decline was observed afterward and fell to USD 68.7 million in 2017. DAH for tuberculosis was limited to less than USD 4.20 million in 2005, and as time went by, it amounted to USD 43.8 million (6.1%) at its maximum in 2015. Tuberculosis consistently occupied less than 8% of total DAH between 2005 and 2017. The DRC experienced several EVD outbreaks during the study period, and DAH for EVD was recorded for responding to outbreaks. However, EVD does not have an overwhelming impact on total DAH. In 2005, the total DAH for West Africa was USD 121 million, and the two dominant categories, HIV/AIDS (22.8%) and malaria (16.5%), were followed by VPDs (5.6%). While minor decreases were observed in 2011 and 2013, there was an upward tendency of total DAH on the whole, which exceeded USD 300 million in 2012, and HIV/AIDS and malaria continuously comprised the larger proportion. It quickly soared to USD 1.22 billion in 2014 and finally peaked at USD 1.58 billion in 2015 before plummeting to USD 525 million in 2017, due to a surge of DAH for EVD from USD 662 million in 2014 to USD 1.12 billion in 2015, which constituted 70.7% of total DAH for that year.

The breakdown of DAH for each country in West Africa and exact values are presented in Supplementary Figure S1 and Supplementary Table S1, respectively. In 2005, the total DAH for Liberia was only USD 25.0 million, which was below compared to DAH received by Guinea (USD 44.8 million) and less than half of Sierra Leone (USD 51.1 million). However, it has jumped up to USD 82.4 million in 2008, which was higher compared to the other two countries, and the trend continued by 2013. Among the disease category, HIV/AIDS was more funded compared in the pre-emergency period in Sierra Leone except in 2006, while in Liberia, the amount of DAH for malaria generally exceeded DAH for HIV/AIDS, except for some changes in 2007 and 2013. DRC received higher investment through DAH compared to countries in West Africa. The total DAH for the DRC continued to grow to USD 821 million in 2017. In 2005-2008, investment for HIV/AIDS accounted for more than 20% of total DAH. DAH for malaria dramatically increased to USD 199 million in 2012, which constituted 28.7% of total DAH, and continuously exceeded that DAH for HIV/AIDS in 2012-2017. DAH for VPDs increased to USD 108 million in 2014. However, a marked decline was observed afterward and fell to USD 68.7 million in 2017. DAH for tuberculosis was limited to less than USD 4.20 million in 2005, and as time went by, it amounted to USD 43.8 million (6.1%) at its maximum in 2015. Tuberculosis consistently occupied less than 8% of total DAH between 2005 and 2017. The DRC experienced several EVD outbreaks during the study period, and DAH for EVD was recorded for responding to outbreaks. However, EVD does not have an overwhelming impact on total DAH.

The evolution of DALYs in West Africa and DRC is shown in Figure 2A ,B, respectively.

The evolution of DALYs in West Africa and DRC is shown in Figure 2A ,B, respectively. Table S2 , respectively. Guinea consistently recorded the highest total DALYs among the three countries, which was followed by Sierra Leone. The lowest total disease burden was recorded in Liberia. In Sierra Leone, malaria consistently recorded the highest disease burden among the selected diseases, which was followed by VPDs. A similar trend was observed in Guinea in 2005-2014 and 2017. On the contrary, the disease burden of VPDs has started to exceed that of malaria since 2013. During the emergency period, each country showed different trends. While the disease burden by EVD was recorded the highest in Liberia in 2014, it was the lowest amount in the selected disease category in Guinea in 2014-2015.

In DRC, the all-cause DALYs decreased by more than 4 million during the study period. Among the five disease categories, malaria constituted the largest proportion accounting for 19.3% of all-cause DALYs in 2005. Although this decreased to 6.00 million in 2017, it still dominated 13.5% of total DALYs. VPDs recorded the second-highest disease burden, and DALYs in VPDs stayed at a level of 6.0-6. Table S2 , respectively. Guinea consistently recorded the highest total DALYs among the three countries, which was followed by Sierra Leone. The lowest total disease burden was recorded in Liberia. In Sierra Leone, malaria consistently recorded the highest disease burden among the selected diseases, which was followed by VPDs. A similar trend was observed in Guinea in 2005-2014 and 2017. On the contrary, the disease burden of VPDs has started to exceed that of malaria since 2013. During the emergency period, each country showed different trends. While the disease burden by EVD was recorded the highest in Liberia in 2014, it was the lowest amount in the selected disease category in Guinea in 2014-2015.

In DRC, the all-cause DALYs decreased by more than 4 million during the study period. Among the five disease categories, malaria constituted the largest proportion accounting for 19.3% of all-cause DALYs in 2005. Although this decreased to 6.00 million in 2017, it still dominated 13.5% of total DALYs. VPDs recorded the second-highest disease burden, and DALYs in VPDs stayed at a level of 6.0-6. 

An evolution of DAH per DALYs (DAH/DALYs) in West Africa and DRC in 2005-2017 is presented in Figure 3A ,B, respectively.

An evolution of DAH per DALYs (DAH/DALYs) in West Africa and DRC in 2005-2017 is presented in Figure 3A ,B, respectively. 

This study presented four major findings. First, while there were slight fluctuations, the total DAH for EVD-affected countries demonstrated an increasing trend both in West Africa and DRC and peaked in 2015 in West Africa. During the EVD outbreak in West Africa, EVD became the most funded disease in 2014-2015, and DAH for other infectious diseases appears to have been disrupted. Second, the all-cause DALYs gradually decreased over the study period, and malaria and VPDs respectively constituted the largest and the secondlargest proportions. In both regions, DALYs by disease consistently showed a decreasing trend over the years. In 2014 in West Africa, DALYs of EVD exceeded DALYs of HIV/AIDS and tuberculosis but were less than DALYs of malaria and VPDs. Third, there have been skewed funding allocations in DAH between infectious diseases in the pre-emergency period, compared to their disease burden. DAH/DALYs for HIV/AIDS were generally higher than total DAH/DALYs. However, malaria and tuberculosis showed different trends by country. Over the study period, DAH/DALYs for VPDs were generally lower than total DAH/DALYs in EVD-affected countries. Fourth, DAH was prioritized for EVDs during health emergencies, and DAH for other infectious diseases showed different trends. In 2013-2016 in West Africa, a fluctuation of DAH/DALYs was detected for HIV/AIDS in Liberia and Sierra Leone and for malaria in Guinea and Liberia. However, VPDs and tuberculosis consistently recorded lower ratios than total DAH/DALYs.

Our study suggested that tuberculosis and VPDs have recorded relatively lower ratios of DAH/DALYs compared to HIV/AIDS and malaria in the pre-emergency period. The emergence of global targets that specify clear goals and targets regarding HIV/AIDS and malaria might have affected the consideration process of allocating DAH. Especially in the United Nations (UN) Millennium Development Goals (MDGs), tuberculosis was only included among "other diseases" in Target [53] , which could potentially bring the disproportionate DAH allocation between infectious diseases.

In addition, the characteristics of each disease might have contributed to skewing attention toward each infectious disease. Tuberculosis was relatively neglected compared to HIV/AIDS and malaria, as challenges in tuberculosis were featured mainly among HIV co-infected cases. This was different from malaria, which records increasing morbidity and mortality among patients with drug-resistant strains, which are recognized as a substantial threat for controlling its spread. Furthermore, there are differences in these diseases' clinical characteristics. While malaria could be recognized as an acute illness in a period of days and weeks after infection, tuberculosis typically develops slowly, and symptoms may not emerge until months or years after infection. Even patients infected with latent tuberculosis will not exhibit any symptoms, making it difficult to securitize tuberculosis. On the other hand, VPDs have been continuously conceptualized not as a security agenda but merely as issues in public health, possibly as they were not health threats in many developed countries where vaccination programs are available, skewing the attention as a global political agenda.

Further, differences between EVD-affected countries need to be further scrutinized. In the pre-emergency period in West Africa, each country has shown different trends of DAH/DALYs by disease category. Especially, while the DAH/DALYs of malaria in Liberia consistently exceeded the total DAH/DALYs except for a dip in 2007, the opposite trend was monitored in Sierra Leone. With regard to DAH/DALYs in tuberculosis, Liberia recorded a higher ratio, and the frequency of exceeding the total DAH/DALYs was higher compared to Guinea and Sierra Leone. These findings indicate further investigation of the relatively higher DAH towards malaria and tuberculosis in Liberia.

Our study also clarified that EVD was disproportionately earmarked for containment during a health emergency. Insufficient preparedness for health emergencies due to a lack of capacity at the national level might have promoted a vertical approach that invested substantial resources in EVD without adequate analysis of overall public health needs. Moreover, despite public awareness and the serious nature of the threat, there has been a sluggish response to the EVD outbreak, as illustrated by the late declaration of a Public Health Emergency of International Concern [54] , which necessitated a vertical approach to visible health threats and dictated unequal resource allocation among diseases, while overlooking the disease burden of endemic diseases and interrupting preventable measures such as vaccination due to health system collapses. DAH/DALYs for diseases that were also threats in EVD-affected countries but have relatively lower risks of transmission for Western countries received far less investment, suggesting the necessity of considering populations in need appropriately.

Regarding other disease categories, while Guinea recorded the higher DAH/DALYs in HIV/AIDS over the total DAH/DALYs even during the EVD outbreaks, similar trends were not observed in Liberia and Sierra Leone, suggesting the necessity of investigating underlying mechanisms between countries. Additionally, although DRC experienced the EVD outbreak in 2014 that recorded 66 cases and 49 deaths, it has been successfully contained within a period of 3 months, which was completely different from the EVD outbreak in West Africa that necessitated year-long responses. The evolution of DAH/DALYs clearly suggested that while the DAH/DALYs in EVD significantly increased for containment in DRC, DAH/DALYs in other categories were not seriously affected due to the quick containment of imminent health emergency.

Although careful examination is required because the overall amount of health spending at the national level is not considered and there are some methodological uncertainties, our study provides a general picture of the limited alignment between DAH for each infectious disease category and each category's disease burden in EVD-affected countries. Our study calls for the evidence-based management of allocating health financing that is scarce. Although there are always competing priorities, using the data of disease burden is critical for making decisions in prioritization, and it is not only limited to the purpose of DAH. To ensure the openness and transparency in funding priorities, the monitoring system of DAH at the global level, as well as health financing at the national level, must be improved. To build a solid foundation for achieving risk reduction during health emergencies, particularly large outbreaks, combining DAH and disease burden for improving the decision making of prioritization in resource allocation, allocating sufficient and appropriate resourcing based on the health needs of populations in both the pre-emergency period and emergency phase, and scrutinizing responses to health emergencies in real-time and revising them accordingly, is pivotal. To achieve these assignments, strengthening the resilience of health systems and incorporating the provision of essential health services into health emergency response plans is imperative to reduce health risks in the post-emergency period. This study explicitly indicated that some disease categories, especially VPDs, were relatively underfunded, and these must be given more priority, and disparities need to be corrected and managed based on the scientific data.

If the trends observed in this study hold true and considering the impact of the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is likely expected that funding for a COVID-19 response in LMICs will increase significantly, while the prevention of other prevalent diseases that pose higher burdens, especially VPDs, may still lack investment. In fact, the disruption of routine childhood immunization programs due to logistic issues, staff shortages, and reallocation of healthcare resources for COVID-19 may result in an increase in the incidence of and deaths from VPDs [55] . The interruption of supplying antiretroviral therapy drugs and provision of preventive measures will engender additional HIV-related deaths [56] . Recent modeling has also suggested that deaths by malaria and tuberculosis will increase by 36% and 20%, respectively, in areas with higher disease burden if the COVID-19 pandemic disrupts crucial prevention activities and healthcare services [57] . Therefore, actors in global health must make efforts to promptly contain the pandemic and secure sufficient resources for other critical issues in public health. This will help balance the responses toward each disease, thus improving population health. Furthermore, the health emergency must prompt healthcare system reform [58] , and both technical challenges that are free from politics and political difficulties require review to maintain essential health services. Comprehensive, multi-sectoral approaches that ensure cost-effectiveness and affordability will promote a positive spillover for addressing the burden of infectious diseases, other disease categories, and health system strengthening.

Several limitations should be noted in the present study. First, this analysis used the data of disbursed DAH and did not evaluate how funds are received and spent at a national level. Utilizing the latter data will prove instrumental to assessing action on the ground. Second, this analysis solely relied on the estimated published by IHME. Globally, there are generally several available data sources, including the Creditor Reporting System (CRS), managed by the Organization for Economic Cooperation and Development (OECD) [59] , and the Financial Tracking Service (FTS), overseen by the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) [60] . While these sources were not used due to a lack of aggregated data on VPDs and EVD and dispersed data on HIV/AIDS, comparative analysis of DAH allocation based on different data sources may help extract challenges of health financing and ultimately improve the current situation of DAH allocation. Additionally, as this study followed the definition of DAH that is presented by IHME, DAH spent on prevention efforts for each disease category might have been insufficiently addressed. Generally, many DAH-related projects aim at building health systems with a specific focus on health areas. While these investments, which are categorized as "other health systems strengthening" in each category, were analyzed in this study, DAH in the category of HSS/SWAps (health system strengthening and sector-wide approaches) are exempted from the analysis. Third, DALYs are useful tools for measuring population health and have been used as a benchmark for health policy; however, several limitations of DALYs, as summarized by Anand and Hanson [61] , and Solberg et al. [62] , must always be noted. Simultaneously, continuous evaluation and further scrutinization of the applicability of DALYs for evaluating the equality of DAH allocation will be pivotal. For example, solely relying on the simple ratio of DAH/DALYs could underestimate potential gains attainable from certain financing in a specific period, especially for infectious diseases that are targeted for eradication (e.g., poliomyelitis) and elimination (e.g., neglected tropical diseases, measles). This point could be complemented with other metrics and by broader standpoints. Fourth, scant research has addressed how to use DALYs as an indicator to measure the impact of health emergencies, and this point necessitates further academic discussion. Fifth, due to data availability, DALYs in polio and rubella are not included in this study, which might possibly help overestimate the DAH/DALYs in VPDs. Sixth, this study used the ratio of DAH to DALYs specific to each category. These metrics have already been used in previous research, but an open investigation is necessary to identify better indicators for determining the amount of DAH because estimates of disease burden are crucial but are not the sole input for prioritization. Finally, it is well known that health expenditures at the national level decrease when the allotment of DAH to governments increases [63] [64] [65] , indicating some challenges in monitoring and evaluation [36] . Combining DAH with domestic health expenditures specific to each disease is a potential idea for tackling this limitation, but comprehensive data are required.

Future research must take these limitations into account and address some of the uncertainties of indicators. Although this analysis could not address the evolution of DAH/DALYs in relation to HIV/AIDS, malaria, tuberculosis, and VPDs during the EVD outbreak in the DRC in 2018-2020 because data are still not available to the public, our analysis of DAH/DALY in West Africa may be indicative of funding during health emergencies. Our analysis can support the hypothesis that investment during the EVD outbreak was disproportionately reserved for EVD at the expense of other diseases, particularly VPDs. Measuring those trends during the post-emergency period in West Africa and in the emergency phase in the DRC can be the research topic in the near future. Furthermore, the coronavirus disease 2019 (COVID-19) pandemic will affect population health to a substantial degree, and the amount of DAH is expected to surge over the next several years. Therefore, investigation of DAH/DALYs in COVID-19 and comparison of ratios with other disease categories are potentially valuable research avenues.

This study has highlighted the evolution of DAH and disease burden in EVD-affected countries both in the pre-emergency period and emergency phase. A skewed funding allocation between infectious diseases in the pre-emergency period was observed. To achieve the risk reduction during and after health emergencies, optimal funding allocation among infectious diseases based on the disease burden is warranted in the pre-emergency period. Additionally, measuring the immediate health needs of populations in real-time will be pivotal. Controlling infectious diseases and the prioritization of funding for each disease is a globally significant agenda and not limited to countries affected by EVD outbreaks. Every country receiving DAH has confronted the same concern and must determine the best strategies for optimal health financing allocation during health emergencies. Our study presents an opportunity to learn from challenges that the EVD outbreak has brought to health financing and prioritization among different infectious diseases. The evidence presented will help all levels of decision-makers to promote evidence-based policymaking for achieving fair allocation of funding among infectious diseases before and during health emergencies. Table S1 : DAH (thousand dollars) for EVD-affected countries, Table S2 : DALYs (thousands) in EVD-affected countries, Table S3 : DAH/DALYs in EVD-affected countries.

Author Contributions: Conceptualization, K.S.; methodology, K.S. and A.W.; software, K.S.; validation, K.S., F.C. and A.W.; formal analysis, K.S.; investigation, K.S.; resources, K.S. and A.W.; data curation, K.S.; writing-original draft preparation, K.S.; writing-review and editing, K.S., F.C. and A.W.; visualization, K.S.; supervision, F.C. and A.W.; project administration, K.S. and A.W.; funding acquisition, F.C. and A.W. All authors have read and agreed to the published version of the manuscript. 

Data Availability Statement: The data are publicly available at websites cited on references [45, 46, 52] .

Ebola Virus Disease Distribution Map: Cases of Ebola Virus Disease in Africa Since

Ebola Outbreak Distribution in West Africa

World Health Organization. 10th Ebola Outbreak in the Democratic Republic of the Congo Declared over; Vigilance against Flare-Ups and Support for Survivors Must Continue

Epidemic in DRC Is One of World's "Most Complex Health Emergencies

Ebola and War in the Democratic Republic of Congo

The Exacerbation of Ebola Outbreaks by Conflict in the Democratic Republic of the Congo

Magnitude of Ebola Relative to Other Causes of Death in Liberia

The Lancet Infectious Diseases. Rationality and Coordination for Ebola Outbreak in West Africa

Effects of Response to 2014-2015 Ebola Outbreak on Deaths from Malaria, HIV/AIDS, and Tuberculosis

The Counter Effects of the Ebola Epidemic on Control and Treatment of HIV/AIDS, Tuberculosis, and Malaria in West Africa

Impact of Infectious Disease Epidemics on Tuberculosis Diagnostic, Management, and Prevention Services: Experiences and Lessons from the 2014-2015 Ebola Virus Disease Outbreak in West Africa

Fragile Health Systems and Tuberculosis Care: A Call for Pre-Emptive Action and Operational Research

Evaluation of the Performance of the National Tuberculosis Program of Liberia during the 2014-2015 Ebola Outbreak

The Health Impact of the 2014-15 Ebola Outbreak

Ebola Outbreak Shuts down Malaria-Control Efforts

Effect of the Ebola-Virus-Disease Epidemic on Malaria Case Management in Guinea, 2014: A Cross-Sectional Survey of Health Facilities

Malaria Morbidity and Mortality in Ebola-Affected Countries Caused by Decreased Health-Care Capacity, and the Potential Effect of Mitigation Strategies: A Modelling Analysis

Non-Communicable Diseases in the Western Area District, Sierra Leone, before and during the Ebola Outbreak

Effect of Ebola Virus Disease on Maternal and Child Health Services in Guinea: A Retrospective Observational Cohort Study

Services for Mothers and Newborns during the Ebola Outbreak in Liberia: The Need for Improvement in Emergencies

Effect of the 2014/2015 Ebola Outbreak on Reproductive Health Services in a Rural District of Guinea: An Ecological Study

Impact of Ebola Experiences and Risk Perceptions on Mental Health in Sierra Leone

Fear and Culture: Contextualising Mental Health Impact of the 2014-2016 Ebola Epidemic in West Africa

Outbreaks of Cholera in the Time of Ebola: Pre-Emptive Action Needed

Measles Cases during Ebola Outbreak

Reduced Vaccination and the Risk of Measles and Other Childhood Infections Post-Ebola

As Ebola Fades, a New Threat

Impact of the Ebola Outbreak on Routine Immunization in Western Area, Sierra Leone-A Field Survey from an Ebola Epidemic Area

Sees Rise in Deaths from Malaria, Measles, and Cholera as Ebola Outbreak Swallows up Resources

Democratic Republic of Congo (DRC)-Cholera Outbreak (UN, DRC Authorities, DG ECHO) (ECHO Daily Flash of 13

World Health Organization. Measles and Rubella Surveillance Data

Impact of a Free Care Policy on the Utilisation of Health Services during an Ebola Outbreak in the Democratic Republic of Congo: An Interrupted Time-Series Analysis

Tracking Development Assistance for Reproductive, Maternal, Newborn, Child and Adolescent Health in Conflict-Affected Countries

Development Assistance for Health in Central and Eastern European Region

Global Health Development Assistance Remained Steady In

Regional Variation in the Allocation of Development Assistance for Health

Vast Majority of Development Assistance for Health Funds Target Those Below Age Sixty

Official Development Assistance for Health-How Neglected Are Neglected Tropical Diseases? An Analysis of Health Financing

Global Development Assistance for Adolescent Health from

Development Assistance for Health: Past Trends, Associations, and the Future of International Financial Flows for Health

Donor Financing of Global Mental Health

Tracking Development Assistance for Health to Fragile States

Patterns of Funding Allocation for Tuberculosis Control in Fragile States

Available online: http: //ghdx.healthdata.org/record/ihme-data/development-assistance-health-database

Institute for Health Metrics and Evaluation. Financing Global Health 2018: Countries and Programs in Transition

Institute for Health Metrics and Evaluation. Terms Defined

Quantifying Disability: Data, Methods and Results

Ad Hoc Committee on Health Research Relating to Future Intervention Options. In Investing in Health Research and Development; World Health Organization

Institute for Health Metrics and Evaluation. Health Financing Publications

Global Burden of Disease Collaborative Network. Global Burden of Disease Study

Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa

Routine Childhood Immunisation during the COVID-19 Pandemic in Africa: A Benefit-Risk Analysis of Health Benefits versus Excess Risk of SARS-CoV-2 Infection

Potential Effects of Disruption to HIV Programmes in Sub-Saharan Africa Caused by COVID-19: Results from Multiple Mathematical Models

Potential Impact of the COVID-19 Pandemic on HIV, Tuberculosis, and Malaria in Low-Income and Middle-Income Countries: A Modelling Study

Organisation for Economic Co-Operation and Development. Technical Guide to Terms and Data in the Creditor Reporting System (CRS) Aid Activities Database

United Nations Office for the Coordination of Humanitarian Affairs

Disability-Adjusted Life Years: A Critical Review

The Devils in the DALY: Prevailing Evaluative Assumptions

Public Financing of Health in Developing Countries: A Cross-National Systematic Analysis

The Fungibility of Health Aid: Reconsidering the Reconsidered

Measuring the Displacement and Replacement of Government Health Expenditure

Acknowledgments: K.S. thanks Makoto Shigei (Uppsala University/Swedish University of Agricultural Sciences) for comments on visualization.

The authors declare no conflict of interest.